Home›Stock Screener›Medicamen Organics›Financial Statements

Medicamen Organics Financial Statements

3 Years of Data
2026 - 2024

Medicamen Organics financial statements. In FYNone, Medicamen Organics (MEDIORG) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of -17.4% and ROE of -13.8%. Full financial statements from FY2024 to FY2026 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore Medicamen Organics intrinsic price to estimate fundamental worth using multiple valuation models.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin -17.39% 2026 data
EBITDA Margin -17.39% 2026 data
Operating Margin -17.00% 2026 data
Return on Assets -7.69% 2026 data
Return on Equity -13.79% 2026 data

Balance Sheet Ratios

Equity Ratio 55.77% 2026 data
Asset Turnover 0.44 2026 data

MEDIORG Revenue, Net Profit & EBITDA — Year-on-Year Growth

MEDIORG YoY (March 2026 vs Period) — revenue -100.0%, net profit +100.0%, EBITDA +100.0%, expenses -100.0%. See Medicamen Organics P/B valuation to compare market price against book value per share.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
+100.0%
Year-over-Year
EBITDA Growth
+100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
-11.9%
Year-over-Year
Equity Growth
-6.5%
Year-over-Year
Financing Cash Flow Growth
-63.6%
Year-over-Year

MEDIORG Income Statement — Revenue, EBITDA & Net Profit

Medicamen Organics revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin -17.4%. For live price, earnings ratios and company overview, see MEDIORG share price.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024
Revenue 0 23 38 25
Expenses 0 26 32 21
EBITDA 0 -4 7 5
Operating Profit Margin % 0.00% -17.00% 17.00% 19.00%
Depreciation 0 1 1 1
Interest 0 1 1 1
Profit Before Tax 0 -5 5 4
Tax 0 -1 1 2
Net Profit 0 -4 4 3
Earnings Per Share (₹) 0.00 -3.41 3.67 3.47

MEDIORG Balance Sheet — Assets, Liabilities & Shareholders' Equity

MEDIORG total assets ₹52 Cr, total equity ₹29 Cr, total liabilities ₹ Cr (2026) — ROE -13.8%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024
ASSETS
Total Assets 52 59 38
Current Assets
Fixed Assets 13 10 10
Capital Work in Progress 0 2 0
Investments 0 0 0
Other Assets 38 47 28
LIABILITIES
Total Liabilities
Current Liabilities 1 2 2
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 29 31 15
Share Capital 12 12 9
Reserves & Surplus 17 18 7

MEDIORG Cash Flow Statement — Operating, Investing & Financing

Medicamen Organics operating cash flow ₹-5 Cr, investing ₹-2 Cr, financing ₹4 Cr, net cash flow ₹-3 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024
Operating Activities -5 -5 -4
Investing Activities -2 -2 0
Financing Activities 4 11 4
Net Cash Flow -3 4 0